Cholangiocarcinoma: The most common adverse reactions (incidence ≥ 20%) are hyperphosphatemia, alopecia, diarrhea, nail toxicity, fatigue, dysgeusia, nausea, constipation, stomatitis, dry eye, dry mouth, decreased ppetite, vomiting, arthralgia, abdominal pain, hypophosphatemia, back pain, and dry skin.
Myeloid/lymphoid neoplasms with FGFR1 rearrangement: The most ommon (≥ 20%) adverse reactions are hyperphosphatemia, nail toxicity, alopecia, stomatitis, diarrhea, dry eye, fatigue, rash, abdominal pain, anemia, constipation, dry mouth, epistaxis, serous retinal detachment, extremity pain, decreased appetite, dry skin, dyspepsia, back pain, nausea, blurred vision, peripheral edema, and dizziness.
from FDA,2022.08
Pemigatinib is a targeted therapy drug that is of great significance in the trea···【more】
Release date:2024-08-14Recommended:114
Pemigatinibis primarily used for the treatment of adult patients with advanced, ···【more】
Release date:2024-08-14Recommended:120
Pemigatinibhas demonstrated significant efficacy in the treatment of cholangioca···【more】
Release date:2024-08-14Recommended:144